The 10 Best Pharma and Biotech Conferences in 2027

1JPMorgan Healthcare Conference

JPMorgan Healthcare Conference ranks first because it is the largest and most influential gathering in the sector, typically drawing over 8,000 attendees and more than 500 presenting companies to San Francisco each January. The 2027 edition will again anchor the entire biotech calendar, with deal announcements and partnership talks that set the tone for the year. No other event concentrates this much C-suite decision-making power in a single week.

It is built for executives, investors, and business development teams rather than bench scientists. The trade-off is cost and exclusivity: registration runs into the thousands and many sessions are invitation-only. Compared to the scientific meetings ranked below it, JPMorgan is a dealmaking venue first and a data-sharing venue second.

2BIO International Convention

BIO International Convention takes second place as the world's largest biotech partnering event, regularly hosting over 15,000 attendees from 65-plus countries and facilitating tens of thousands of pre-scheduled one-on-one meetings. The 2027 convention will again feature its signature BIO One-on-One Partnering platform, which books meetings months in advance. Its sheer scale makes it the broadest single venue for licensing and collaboration.

It suits business development professionals, startup founders, and investors hunting partnerships rather than researchers seeking deep science. The trade-off is a sprawling, impersonal floor where meaningful conversations require pre-booking. Compared to JPMorgan above, BIO is more accessible and less exclusive, but it lacks the concentrated investor gravity of that January week.

3ASCO Annual Meeting

ASCO Annual Meeting ranks third as the definitive oncology conference, typically drawing over 40,000 attendees and presenting thousands of abstracts that frequently move drug approvals and clinical practice. The 2027 meeting will again showcase pivotal trial readouts in immunotherapy, targeted therapy, and cell therapy. For cancer drug developers, no other scientific venue carries comparable media and regulatory weight.

It is aimed at oncologists, clinical researchers, and pharma teams with oncology pipelines. The trade-off is overwhelming scale and overlapping sessions that force hard scheduling choices. Compared to BIO above, ASCO is science-and-data driven rather than deal-driven, making it essential for R&D leaders but less central for pure business development.

4American Society of Hematology Meeting

ASH Annual Meeting takes fourth place as the premier hematology event, attracting around 30,000 attendees and presenting more than 5,000 abstracts on blood cancers, gene therapy, and sickle cell disease. The 2027 meeting will again be where CAR-T and gene-editing data debut to a specialist audience. Its influence on hematology approvals and practice guidelines is unmatched.

It serves hematologists, translational researchers, and companies developing blood-disease therapies. The trade-off is a narrow focus that offers little for professionals outside hematology and oncology. Compared to ASCO above, ASH is smaller and more specialized, trading breadth for depth that specialists genuinely need.

5American Association for Cancer Research Annual Meeting

AACR Annual Meeting secures fifth place as the leading basic and translational cancer research conference, drawing over 20,000 attendees and presenting more than 7,000 abstracts spanning tumor biology, prevention, and early-phase trials. The 2027 meeting will again emphasize preclinical discovery and biomarker science. It is the earliest venue where emerging cancer targets gain visibility.

It is designed for academic scientists, early-stage biotech researchers, and discovery-focused pharma teams. The trade-off is a research-heavy program with less late-stage clinical and commercial content. Compared to ASH above, AACR skews earlier in the pipeline, making it ideal for discovery scientists but less useful for those tracking approved therapies.

6American Diabetes Association Scientific Sessions

ADA Scientific Sessions ranks sixth as the largest diabetes-focused meeting, typically gathering around 15,000 attendees and presenting thousands of abstracts on insulin, GLP-1 therapies, and continuous glucose monitoring. The 2027 sessions will again highlight obesity and metabolic disease data amid surging demand. It is the central venue for cardiometabolic drug developers.

It suits endocrinologists, metabolic researchers, and pharma teams working on diabetes and obesity. The trade-off is a disease-specific scope that limits relevance for broader biotech professionals. Compared to AACR above, ADA is more clinically oriented and commercially charged, reflecting the enormous market stakes in metabolic medicine.

7American College of Cardiology Scientific Session

ACC Scientific Session takes seventh place as the foremost cardiovascular meeting, drawing roughly 15,000 attendees and presenting late-breaking trials that regularly reshape heart-failure, lipid, and anticoagulation guidelines. The 2027 session will again feature major outcomes trials with immediate clinical impact. Its trial readouts often drive same-week media coverage.

It is built for cardiologists, clinical trialists, and cardiovascular drug and device developers. The trade-off is a focus that excludes oncology, immunology, and rare-disease audiences. Compared to ADA above, ACC covers a different therapeutic giant but shares the same clinically driven, guideline-shaping character.

8American Society of Clinical Oncology Breakthrough

ASCO Breakthrough ranks eighth as a newer, innovation-focused meeting that condenses cutting-edge oncology science into a compact, interactive format drawing several thousand attendees. The 2027 edition will again spotlight emerging technologies, AI in oncology, and early-career research. It offers a faster, less overwhelming alternative to the flagship ASCO meeting.

It targets early-career oncologists, tech-forward researchers, and small biotech teams seeking agility. The trade-off is smaller scale and less prestige than the main ASCO Annual Meeting. Compared to ACC above, ASCO Breakthrough is more experimental and intimate, trading the giant stage for quicker access to speakers and collaborators.

9European Society for Medical Oncology Congress

ESMO Congress ranks ninth as Europe's flagship oncology meeting, attracting over 30,000 attendees and presenting practice-changing trials with strong representation from European regulators and health systems. The 2027 congress will again serve as the key venue for EMA-relevant oncology data. Its global reach complements the US-centric ASCO calendar.

It is aimed at European oncologists, international researchers, and companies seeking EU market traction. The trade-off is travel cost and a program that partly duplicates ASCO content. Compared to ASCO Breakthrough above, ESMO is larger and more established, offering regulatory context that the smaller innovation meeting does not.

10Festival of Biologics

Festival of Biologics rounds out the list as a focused European event dedicated to biologics, cell and gene therapy, and manufacturing science, drawing several thousand specialists. The 2027 edition will again emphasize CMC, analytics, and process development across multiple tracks. It fills a niche that broad oncology meetings largely ignore.

It suits bioprocess engineers, CMC scientists, and manufacturing-focused biotech teams. The trade-off is a technical scope with little commercial or clinical content. Compared to ESMO above, Festival of Biologics is far smaller and more operational, serving the people who make therapies rather than those who prescribe them.

How we ranked these

We ranked 2027 pharma and biotech conferences by weighting attendee seniority mix, deal-flow density, therapeutic-area relevance across oncology, immunology, and rare disease, and the ratio of partnering meetings to lecture hours. Scores also factored exhibitor quality, payer and regulator presence, and geographic access for global teams. Events were scored on published 2026-2027 agendas, historical attendance data, and verified post-event reports rather than marketing copy.

We deliberately ignored booth square footage, sponsorship tier pricing, and keynote celebrity wattage, since these inflate cost without improving scientific or commercial return. We excluded conferences with unverifiable attendance claims or no published agenda. Regional trade shows with purely local audiences were dropped, as were virtual-only events, because serendipitous hallway meetings and in-person partnering remain the primary reason teams travel.

What to look for

Choose based on your goal: licensing and BD teams need partnering-heavy events with pre-scheduled one-on-one systems, while R&D and clinical leads get more from scientific tracks with unpublished data. Check the attendee list from the prior year, not the projected one. Confirm whether payers, regulators, and KOLs actually attend or just appear in promotional material.

The mistake most buyers make is booking by brand recognition alone, then sending junior staff who cannot close conversations. A second common error is buying exhibition space before confirming meeting-room availability, which leaves teams stranded in a hall far from the partnering floor. Budget for follow-up travel and side meetings, since the real value often happens off-site.

Related questions

What is the best pharma conference for business development and licensing?

Partnering-focused events with pre-booked one-on-one meeting systems deliver the highest deal density. Look for conferences that publish attendee seniority data and cap attendance to keep the ratio of decision-makers high. Events tied to major therapeutic clusters, especially oncology and rare disease, tend to attract BD leads actively scouting assets.

How far in advance should I register for a 2027 biotech conference?

Most major events open registration nine to twelve months ahead, and early rates typically close four to six months before the date. Hotel blocks near the venue sell out first, often within weeks of opening. For partnering-heavy conferences, submit your meeting requests as soon as the platform opens, since top targets fill calendars fast.

Are virtual or hybrid biotech conferences worth attending in 2027?

Hybrid formats work for scientific updates and regulatory briefings, where content is the main draw. They underperform for deal-making, because spontaneous hallway conversations and dinner meetings drive most partnerships. If your goal is licensing, hiring, or investor outreach, attend in person. Use virtual options to cover sessions you would otherwise skip.

Which therapeutic areas dominate 2027 pharma conference agendas?

Oncology remains the largest track, followed by immunology, neurology, and rare disease. Cell and gene therapy, radiopharmaceuticals, and obesity-adjacent metabolic programs are expanding fastest. AI-driven drug discovery and real-world evidence sessions now appear across nearly every major agenda, reflecting regulatory and payer interest rather than pure hype.

How do I justify conference travel budget to finance or leadership?

Tie attendance to specific outcomes: number of pre-scheduled partnering meetings, target accounts met, and pipeline assets reviewed. Track post-event follow-ups and convert them into a simple cost-per-qualified-lead figure. Compare that against your other lead-generation channels. Conferences with published attendee lists make this justification far easier to defend.

What should I bring to a pharma partnering conference?

Bring a one-page non-confidential asset summary, a clear ask, and a follow-up plan with named owners. Load your calendar with buffer time between meetings, since sessions run back-to-back. Carry printed backup materials in case Wi-Fi fails. Most importantly, decide in advance which deals you will walk away from, so you do not waste slots.

Do I need a booth to get value from a biotech conference?

No. For most biotechs, a partnering pass plus a small meeting room outperforms a booth. Booths work for platform companies and service providers generating inbound interest. If your goal is one-on-one BD conversations, invest in the partnering platform and pre-booked meetings instead. Booth space is expensive and rarely converts on its own.

How do I choose between two similar conferences in the same year?

Compare prior-year attendee lists, not projected ones. Check whether your top twenty target companies attended and whether their BD leads were present. Review the partnering platform's meeting statistics if published. Then weigh travel cost and timing against your internal milestones. Attending both is rarely justified unless your pipeline spans two distinct therapeutic areas.

FAQ

What makes a pharma conference worth attending in 2027?

Worth comes from who attends and what they can decide. Prioritize events where BD leads, chief scientific officers, and regulators are present in meaningful numbers. Published attendee lists, prior-year partnering statistics, and a focused therapeutic agenda are stronger signals than stage size or sponsor logos. If your target contacts are absent, the event is not worth the travel.

How many major pharma and biotech conferences happen each year?

Hundreds globally, but only roughly twenty to thirty carry real international deal flow and scientific weight. The rest are regional, vendor-led, or narrowly specialized. Most teams realistically attend three to five per year, split between one large flagship event and several focused therapeutic or partnering meetings. Attending more rarely improves outcomes.

Which conference is best for early-stage biotech startups?

Startups get the most from partnering events with structured one-on-one meeting systems and investor tracks. Smaller, therapeutic-focused conferences often beat mega-events because senior BD leads are more accessible. Look for pitch sessions, BIO-style partnering platforms, and events where large pharma scouting teams attend specifically to review early assets.

How important is location when choosing a conference?

Location affects cost, visa logistics, and who attends. US and European hubs draw the broadest international mix, while regional events attract mainly local participants. Consider jet lag and travel time if your team is presenting or running back-to-back meetings. A slightly weaker agenda in an accessible city often beats a stronger one requiring two connections.

What is the typical cost of attending a major pharma conference?

Registration for flagship events commonly runs several thousand dollars, with partnering fees added separately. Flights, hotels, and meals can double that figure, especially in expensive host cities. Booth space adds significantly more. Budget for follow-up travel and side meetings too, since off-site conversations often produce the best returns.

Can I get meaningful value from a conference without presenting?

Yes. Most attendees never present and still generate strong returns through partnering meetings, hallway conversations, and session Q&A. Presenting helps visibility but is not required for deal flow. What matters is preparation: a clear asset summary, a defined ask, and pre-booked meetings with the right people before you arrive.

How do I measure return on investment from a conference?

Track pre-booked meetings held, qualified follow-ups, and pipeline assets advanced. Assign a cost-per-qualified-lead figure and compare it against your other channels. Qualitative wins, such as competitive intelligence or regulatory insight, should be logged too. Review results ninety days after the event, since deals rarely close on-site.

What are the biggest mistakes at pharma conferences?

Sending junior staff without decision authority, over-scheduling without buffer time, and treating the event as a booth-marketing exercise rather than a meeting-driven one. Another common error is failing to follow up within a week, when memory and momentum fade. Skipping the partnering platform entirely also wastes the highest-value part of most events.

Are there conferences specifically for regulatory and clinical affairs professionals?

Yes. Several major industry events run dedicated regulatory, pharmacovigilance, and clinical operations tracks, and some standalone meetings focus entirely on these functions. These are valuable for teams tracking FDA and EMA guidance changes, trial design trends, and payer evidence requirements. They typically draw fewer BD leads but deeper functional expertise.

How has the pharma conference landscape changed for 2027?

Agendas now emphasize AI-enabled discovery, cell and gene therapy manufacturing, radiopharmaceuticals, and real-world evidence. Payer and health-economics content has grown substantially. Hybrid attendance persists but in-person partnering remains dominant. Smaller, therapeutic-specific events continue gaining ground against mega-conferences, as teams prioritize meeting quality over sheer attendee volume.

Sources

• https://www.biospace.com
• https://www.fiercebiotech.com
• https://www.statnews.com
• https://www.nature.com/subjects/biotechnology
• https://www.bio.org/events
• https://www.dcatvci.org
• https://www.ascopost.com
• https://www.pharmexec.com
• https://www.reutersevents.com/pharma
• https://www.clinicaltrialsarena.com

Related on PULSE

• More pharma and biotech conferences rankings and buying guides
• PULSE Tools and calculators
• Everything on PULSE RevOps